Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
- Update frequency
- every 5 days
- Episodes
- 347
- Years Active
- 2015 - 2025
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Guest: Thomas Egenod, MD
In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2…
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Guest: Thomas Egenod, MD
In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2…
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Guest: Aaron Lisberg, MD
Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung ca…
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Guest: Alex Spira, MD, PhD, FACP
Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but wha…
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01…
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01…
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Guest: Alex Spira, MD, PhD, FACP
Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but wha…
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Guest: Aaron Lisberg, MD
Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung ca…
Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options
Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who …
Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options
Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who …
The Future of ITP Care: Exploring New Treatments
New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targ…
Understanding iMCD Through RNA Sequencing
New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has …
Understanding iMCD Through RNA Sequencing
New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has …
The Future of ITP Care: Exploring New Treatments
New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targ…
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Guest: Marina Garassino, MD
Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in pat…
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Guest: Marina Garassino, MD
Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in pat…
Diagnosing Castleman Disease: Key Considerations
Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition. Early diagnosis through excisional biopsies is key for speeding up treatment …
Diagnosing Castleman Disease: Key Considerations
Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition. Early diagnosis through excisional biopsies is key for speeding up treatment …
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Castleman disease is difficult to diagnose and treat, with half of patients not responding to therapy. To address these challenges, Dr. Joshua Brand…
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Castleman disease is difficult to diagnose and treat, with half of patients not responding to therapy. To address these challenges, Dr. Joshua Brand…